| The role of uptake and efflux transporters in the disposition of glucuronide and sulfate conjugates E Järvinen, F Deng, W Kiander, A Sinokki, H Kidron, N Sjöstedt Frontiers in Pharmacology 12, 802539, 2022 | 71 | 2022 |
| Comparative hepatic and intestinal efflux transport of statins F Deng, SK Tuomi, M Neuvonen, P Hirvensalo, S Kulju, C Wenzel, ... Drug Metabolism and Disposition 49 (9), 750-759, 2021 | 50 | 2021 |
| Pharmacokinetic simulations of intravitreal biologicals: aspects of drug delivery to the posterior and anterior segments AK Rimpelä, I Kiiski, F Deng, H Kidron, A Urtti Pharmaceutics 11 (1), 9, 2018 | 42 | 2018 |
| Comparative hepatic and intestinal metabolism and pharmacodynamics of statins AM Filppula, P Hirvensalo, H Parviainen, VE Ivaska, KI Lönnberg, F Deng, ... Drug Metabolism and Disposition 49 (8), 658-667, 2021 | 39 | 2021 |
| Febuxostat, but not allopurinol, markedly raises the plasma concentrations of the breast cancer resistance protein substrate rosuvastatin M Lehtisalo, JE Keskitalo, A Tornio, O Lapatto‐Reiniluoto, F Deng, ... Clinical and translational science 13 (6), 1236-1243, 2020 | 38 | 2020 |
| Efflux transport of estrogen glucuronides by human MRP2, MRP3, MRP4 and BCRP E Järvinen, F Deng, H Kidron, M Finel The Journal of Steroid Biochemistry and Molecular Biology 178, 99-107, 2018 | 33 | 2018 |
| Interaction of food additives with intestinal efflux transporters N Sjostedt, F Deng, O Rauvala, T Tepponen, H Kidron Molecular Pharmaceutics 14 (11), 3824-3833, 2017 | 31 | 2017 |
| General pharmacokinetic model for topically administered ocular drug dosage forms F Deng, VP Ranta, H Kidron, A Urtti Pharmaceutical research 33, 2680-2690, 2016 | 26 | 2016 |
| The effect of albumin on MRP2 and BCRP in the vesicular transport assay F Deng, N Sjöstedt, H Kidron PLoS One 11 (10), e0163886, 2016 | 24 | 2016 |
| Novel inhibitors of breast cancer resistance protein (BCRP, ABCG2) among marketed drugs F Deng, N Sjöstedt, M Santo, M Neuvonen, M Niemi, H Kidron European Journal of Pharmaceutical Sciences 181, 106362, 2023 | 22 | 2023 |
| Binding site interactions of modulators of breast cancer resistance protein, multidrug resistance-associated protein 2, and p-glycoprotein activity F Deng, L Ghemtio, E Grazhdankin, P Wipf, H Xhaard, H Kidron Molecular Pharmaceutics 17 (7), 2398-2410, 2020 | 19 | 2020 |
| Food additives as inhibitors of intestinal drug transporter OATP2B1 A Tikkanen, E Pierrot, F Deng, VB Sánchez, M Hagström, JB Koenderink, ... Molecular Pharmaceutics 17 (10), 3748-3758, 2020 | 13 | 2020 |
| A structure-activity relationship study of ABCC2 inhibitors G Wissel, F Deng, P Kudryavtsev, L Ghemtio, P Wipf, H Xhaard, H Kidron European Journal of Pharmaceutical Sciences 103, 60-69, 2017 | 13 | 2017 |
| Rhabdomyolysis during concomitant ticagrelor and rosuvastatin: A breast cancer resistance protein‐mediated drug interaction? M Lehtisalo, W Kiander, AM Filppula, F Deng, H Kidron, M Korhonen, ... British Journal of Clinical Pharmacology 89 (7), 2309-2315, 2023 | 10 | 2023 |
| Toxicity and therapy outcome associations in LIG3, SLCO1B3, ABCB1, OPRM1 and GSTP1 in high‐grade serous ovarian cancer F Deng, M Laasik, L Salminen, L Lapatto, K Huhtinen, Y Li, S Hautaniemi, ... Basic & Clinical Pharmacology & Toxicology 132 (6), 517-527, 2023 | 3 | 2023 |
| Ticagrelor modestly raises plasma riboflavin concentration in humans and inhibits riboflavin transport by BCRP and MRP4 F Deng, K Hämäläinen, M Lehtisalo, M Neuvonen, M Niemi Clinical Pharmacology & Therapeutics, 2024 | 2 | 2024 |
| Inhibition of efflux transporters by poly ADP‐ribose polymerase inhibitors F Deng, J Sistonen, M Neuvonen, M Niemi Basic & Clinical Pharmacology & Toxicology 133 (4), 428-436, 2023 | 2 | 2023 |
| Lisääkö tikagrelorin käyttö rosuvastatiinin lihashaittariskiä? M Lehtisalo, W Kiander, AM Filppula, F Deng, H Kidron, M Korhonen, ... Duodecim 139 (6), 463, 2023 | | 2023 |
| Toxicity and therapy outcome associations in LIG3 F Deng, M Laasik, L Salminen, L Lapatto, K Huhtinen, Y Li, S Hautaniemi, ... | | 2023 |
| Transport of statins by skeletal muscle efflux transporters S Tuomi, F Deng, M Niemi EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 78 (SUPPL 1), S103-S104, 2022 | | 2022 |